FDA Grants Breakthrough Therapy Designation to Biogen’s Salanersen for SMA
Event summary
- Biogen’s salanersen received FDA Breakthrough Therapy Designation for spinal muscular atrophy (SMA) on June 4, 2026.
- The designation is based on Phase 1b study data showing clinically meaningful improvements in motor function and slowing of neurodegeneration in children previously treated with gene therapy.
- Salanersen is an investigational antisense oligonucleotide (ASO) with once-yearly dosing potential.
- Biogen’s Phase 3 program for salanersen includes three global studies: STELLAR-1, SOLAR, and STELLAR-2.
The big picture
The FDA’s Breakthrough Therapy Designation for salanersen underscores the ongoing unmet needs in SMA treatment and the potential for novel therapies to address gaps left by existing treatments. Biogen’s once-yearly dosing ASO could reshape the SMA treatment paradigm, particularly for patients with suboptimal responses to current therapies. The strategic significance lies in Biogen’s ability to leverage this designation to expedite development and secure a competitive edge in the rare disease space.
What we're watching
- Clinical Efficacy
- How the Phase 3 studies will validate salanersen’s efficacy in a broader SMA patient population.
- Regulatory Pathway
- Whether the Breakthrough Therapy Designation will accelerate salanersen’s approval process.
- Market Positioning
- The pace at which Biogen can differentiate salanersen in the competitive SMA treatment landscape.
Related topics